A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma

Published:2020-12-17 Issue:1 Volume:14 Page:31-45
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Richard Shambavi¹,Jagannath Sundar¹,Cho Hearn Jay¹,Parekh Samir¹,Madduri Deepu¹,Richter Joshua¹,Chari Ajai¹^ORCID

Affiliation:

1. Division of Hematology/Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Funder

funded

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2021.1858790

Reference79 articles.

1. Cancer statistics, 2020

2. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

3. Integration of Novel Agents into the Care of Patients with Multiple Myeloma

4. Maintenance Treatment and Survival in Patients With Myeloma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07

2. Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data;South Russian Journal of Therapeutic Practice;2024-06-24

3. A validated LC-MS/MS method for the quantitation of daratumumab in rat serum using rapid tryptic digestion without IgG purification and reduction;Journal of Pharmaceutical and Biomedical Analysis;2024-06

4. Multiple Myeloma in the Era of Novel Agents and Stem Cell Therapies;Recent Updates on Multiple Myeloma;2023-03-15

5. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients;Onkologie;2022-10-14